133 related articles for article (PubMed ID: 10834272)
1. Intensely cytotoxic anthracycline prodrugs: galactosides.
Bakina E; Farquhar D
Anticancer Drug Des; 1999 Dec; 14(6):507-15. PubMed ID: 10834272
[TBL] [Abstract][Full Text] [Related]
2. Intensely cytotoxic anthracycline prodrugs: glucuronides.
Bakina E; Wu Z; Rosenblum M; Farquhar D
J Med Chem; 1997 Dec; 40(25):4013-8. PubMed ID: 9406592
[TBL] [Abstract][Full Text] [Related]
3. Suicide gene therapy using E. coli beta-galactosidase.
Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
[TBL] [Abstract][Full Text] [Related]
4. Prodrugs of anthracycline antibiotics suited for tumor-specific activation.
Azoulay M; Florent JC; Monneret C; Gesson JP; Jacquesy JC; Tillequin F; Koch M; Bosslet K; Czech J; Hoffman D
Anticancer Drug Des; 1995 Sep; 10(6):441-50. PubMed ID: 7575986
[TBL] [Abstract][Full Text] [Related]
5. Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT.
Kamal A; Tekumalla V; Krishnan A; Pal-Bhadra M; Bhadra U
ChemMedChem; 2008 May; 3(5):794-802. PubMed ID: 18247436
[TBL] [Abstract][Full Text] [Related]
6. Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.
Torgov MY; Alley SC; Cerveny CG; Farquhar D; Senter PD
Bioconjug Chem; 2005; 16(3):717-21. PubMed ID: 15898742
[TBL] [Abstract][Full Text] [Related]
7. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
8. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
Heinis C; Alessi P; Neri D
Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
[TBL] [Abstract][Full Text] [Related]
9. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
Tietze LF; Krewer B
Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
[TBL] [Abstract][Full Text] [Related]
11. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
Tietze LF; Major F; Schuberth I; Spiegl DA; Krewer B; Maksimenka K; Bringmann G; Magull J
Chemistry; 2007; 13(16):4396-409. PubMed ID: 17455190
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy.
Thomas M; Rivault F; Tranoy-Opalinski I; Roche J; Gesson JP; Papot S
Bioorg Med Chem Lett; 2007 Feb; 17(4):983-6. PubMed ID: 17157009
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
15. Novel anthracycline-spacer-beta-glucuronide,-beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy.
Leenders RG; Damen EW; Bijsterveld EJ; Scheeren HW; Houba PH; van der Meulen-Muileman IH; Boven E; Haisma HJ
Bioorg Med Chem; 1999 Aug; 7(8):1597-610. PubMed ID: 10482452
[TBL] [Abstract][Full Text] [Related]
16. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.
Mittal S; Song X; Vig BS; Landowski CP; Kim I; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(1):37-46. PubMed ID: 15804176
[TBL] [Abstract][Full Text] [Related]
17. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.
Tietze LF; Schuster HJ; Krewer B; Schuberth I
J Med Chem; 2009 Jan; 52(2):537-43. PubMed ID: 19143570
[TBL] [Abstract][Full Text] [Related]
19. Beta-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy.
Devalapally H; Navath RS; Yenamandra V; Akkinepally RR; Devarakonda RK
Arch Pharm Res; 2007 Jun; 30(6):723-32. PubMed ID: 17679550
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antiprotozoal activity of aza-analogues of furamidine.
Ismail MA; Brun R; Easterbrook JD; Tanious FA; Wilson WD; Boykin DW
J Med Chem; 2003 Oct; 46(22):4761-9. PubMed ID: 14561095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
